Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys
- PMID:17272677
- DOI: 10.1124/jpet.106.113571
Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys
Abstract
The present study examined the effects of two novel dopamine D3 receptor compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide], an antagonist, and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], a partial agonist, in two models of cocaine abuse in rhesus monkeys. To establish a dose range and time course of effects, both compounds were shown to block quinpirole-induced yawning when administered i.m. 15, 30, or 120 min before quinpirole. Next, rhesus monkeys were trained to discriminate i.m. injections of saline (0.5 ml) and cocaine (0.3 mg/kg). Neither D3 compound (0.03-3.0 mg/kg; n=3) substituted for cocaine in any monkey. When given in combination with cocaine, CJB 090 but not NGB 2904 attenuated the discriminative stimulus effects of cocaine, shifting the cocaine dose-response curve to the right. In a separate group of monkeys, responding was maintained under a second-order schedule of either food (1.0-g pellets; n=3) or cocaine (0.1 mg/kg/injection; n=4) presentation. When responding was stable, a dose of NGB 2904 (1.0-5.6 mg/kg i.v.) or CJB 090 (0.3-3.0 mg/kg i.v.) was administered for 5 consecutive days, immediately before the session. CJB 090, but not NGB 2904, decreased cocaine- and food-maintained responding. These data indicate that compounds with relatively high affinity and selectivity for the D3 receptor can attenuate the discriminative and reinforcing stimulus effects of cocaine while not producing cocaine-like effects. The present findings support the continued examination of D3 compounds as pharmacological tools for better understanding the role of this receptor subtype in cocaine addiction and as potential lead compounds for novel therapeutic agents.
Similar articles
- Effects of varenicline on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.Gould RW, Czoty PW, Nader SH, Nader MA.Gould RW, et al.J Pharmacol Exp Ther. 2011 Nov;339(2):678-86. doi: 10.1124/jpet.111.185538. Epub 2011 Aug 19.J Pharmacol Exp Ther. 2011.PMID:21856860Free PMC article.
- Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse.Mason CW, Hassan HE, Kim KP, Cao J, Eddington ND, Newman AH, Voulalas PJ.Mason CW, et al.J Pharmacol Exp Ther. 2010 Jun;333(3):854-64. doi: 10.1124/jpet.109.165084. Epub 2010 Mar 12.J Pharmacol Exp Ther. 2010.PMID:20228156Free PMC article.
- Dopamine D3 receptors mediate the discriminative stimulus effects of quinpirole in free-feeding rats.Baladi MG, Newman AH, France CP.Baladi MG, et al.J Pharmacol Exp Ther. 2010 Jan;332(1):308-15. doi: 10.1124/jpet.109.158394. Epub 2009 Oct 1.J Pharmacol Exp Ther. 2010.PMID:19797621Free PMC article.
- Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats.Thomsen M, Barrett AC, Butler P, Negus SS, Caine SB.Thomsen M, et al.J Pharmacol Exp Ther. 2017 Jul;362(1):161-176. doi: 10.1124/jpet.117.241141. Epub 2017 May 4.J Pharmacol Exp Ther. 2017.PMID:28473458Free PMC article.
- Influence of cocaine history on the behavioral effects of Dopamine D(3) receptor-selective compounds in monkeys.Blaylock BL, Gould RW, Banala A, Grundt P, Luedtke RR, Newman AH, Nader MA.Blaylock BL, et al.Neuropsychopharmacology. 2011 Apr;36(5):1104-13. doi: 10.1038/npp.2010.248. Epub 2011 Feb 2.Neuropsychopharmacology. 2011.PMID:21289600Free PMC article.
Cited by
- Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.Keck TM, John WS, Czoty PW, Nader MA, Newman AH.Keck TM, et al.J Med Chem. 2015 Jul 23;58(14):5361-80. doi: 10.1021/jm501512b. Epub 2015 Mar 31.J Med Chem. 2015.PMID:25826710Free PMC article.
- Social Monogamy in Nonhuman Primates: Phylogeny, Phenotype, and Physiology.French JA, Cavanaugh J, Mustoe AC, Carp SB, Womack SL.French JA, et al.J Sex Res. 2018 May-Jun;55(4-5):410-434. doi: 10.1080/00224499.2017.1339774. Epub 2017 Jul 13.J Sex Res. 2018.PMID:28704071Free PMC article.Review.
- Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.Newman AH, Blaylock BL, Nader MA, Bergman J, Sibley DR, Skolnick P.Newman AH, et al.Biochem Pharmacol. 2012 Oct 1;84(7):882-90. doi: 10.1016/j.bcp.2012.06.023. Epub 2012 Jul 3.Biochem Pharmacol. 2012.PMID:22781742Free PMC article.Review.
- Neuroscience of behavioral and pharmacological treatments for addictions.Potenza MN, Sofuoglu M, Carroll KM, Rounsaville BJ.Potenza MN, et al.Neuron. 2011 Feb 24;69(4):695-712. doi: 10.1016/j.neuron.2011.02.009.Neuron. 2011.PMID:21338880Free PMC article.Review.
- Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.Heidbreder C.Heidbreder C.Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):167-76. doi: 10.1007/s00210-012-0803-6. Epub 2012 Oct 28.Naunyn Schmiedebergs Arch Pharmacol. 2013.PMID:23104235Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources